An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Registrational
- Sponsors Biogen
- 27 Jun 2017 Interim results (n=163) presented at the 3rd Congress of the European Academy of Neurology
- 24 May 2017 Planned End Date changed from 1 Mar 2019 to 21 May 2018.
- 24 May 2017 Planned primary completion date changed from 1 Mar 2019 to 21 May 2018.